Immunotherapy with ponezumab for probable cerebral amyloid angiopathy.

ABSTRACT:

Objective

Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β-amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double-blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a novel monoclonal antibody against Aβ _1-40.

Methods

Thirty-six participants aged 55-80 years with probable CAA received intravenous placebo (n = 12) or ponezumab (n = 24). The change from baseline to Days 2 and 90 in cerebrovascular reactivity (CVR) was measured in the visual cortex as the natural log of the rising slope of the BOLD fMRI response to a visual stimulus. Safety and tolerability were also assessed.

Results

The mean change from

SUBMITTER: Leurent C 

PROVIDER: S-EPMC6469253 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature